Daiichi Sankyo Co Ltd at JPMorgan Healthcare Conference Transcript
So good morning, everyone. Welcome to the JPMorgan Healthcare Conference. I'm Seiji Wakao, Japan pharma analyst at JPMorgan. It's my great pleasure to introduce Sunao Manabe, Representative Director, President and CEO of Daiichi Sankyo. And from Q&A session, Dr. Ken Takeshita, the Global Head of Research and Development, we join. With that, I'm going to hand it over to Manabe-san.
Okay. Thank you, Wakao-san. Hello colleagues. Thank you for your strong interest in Daiichi Sankyo. Also, I really appreciate the JPMorgan for providing this good opportunity. I'm very happy to back here since 2020. Because of COVID-19, I was not able to participate in this conference last year, also in 2021. Taking this opportunity, I'd like to share the current status of Daiichi Sankyo. Okay, let's go to Slide #3. And today, I will start with a very brief overview of Daiichi Sankyo, then I will present on ENHERTU, our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |